NCT00407121

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Asociación para Evitar la Ceguera en México · Academic / Other
• Sex: All
• Age: 25 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Conditions

• Vogt Koyanagi Harada Disease
• Serpiginous Choroiditis
• Multifocal Choroiditis

Interventions

Type	Name	Description
DRUG	Bevacizumab
PROCEDURE	Intravitreal Injection of Bevacizumab

Timeline

• Start date: 2006-12-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2006-12-04
• Last updated: 2024-05-30

Locations

1 site across 1 country: Mexico